Advanced Oncotherapy (AVO) – Industrialisation agreement with Thales
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has finalised the details of the contract for manufacturing the first LIGHT machine with Thales. This forms part of the partnership with Thales that was announced in February 2016. Thales has selected one of its factories located in France, […]
Advanced Oncotherapy (AVO) – Directorate change
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Nicolas Serandour, Chief Operating Officer and Chief Financial Officer, will become Chief Executive Officer with immediate effect. Michael Sinclair, currently Chief Executive Officer and Executive Chairman, will retain his role as Executive Chairman. Commenting, Dr. Michael Sinclair, Executive Chairman of […]
Advanced Oncotherapy (AVO) secures of £24m financing for Harley Street
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed an agreement with a fund advised by Metric Capital Partners LLP, a pan-European private capital fund manager, whereby Metric Capital will invest £24 million in a financing facility to support the Company’s provision of vendor financing for the […]
Advanced Oncotherapy (AVO) – Strategic Update from Nicolas Serandour
Advanced Oncotherapy (AVO) – COO and CFO Nicolas Serandour is interviewed by BRR Media, and provides an update on AVO’s recent activity including the agreement with Thales and the companies financial strategy. Link here to listen.
Advanced Oncotherapy (AVO) looking at “disrupting” the cancer treatment market
In a Proactive StockTube interview, Nicolas Serandour, chief operating officer (COO) and chief finance officer (CFO) Advanced Oncotherapy (AVO), says the firm is looking at “disrupting the market” with its proton cancer treatment technology.
Advanced Oncotherapy (AVO) – Directorate Change
Advanced Oncotherapy plc (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that following the continued successful development of the Company’s first LIGHT system and the recent industrialisation agreement with Thales, the Board has decided to realign the roles and responsibilities of the Executive team to add additional focus to both operational […]